Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study

INTRODUCTION: Since current treatment options for patients suffering from active rheumatoid arthritis (RA) remain inadequate, especially for those unresponsive to disease-modifying antirheumatic drugs (DMARDs), new and improved medication is needed. This study evaluates the safety and efficacy of ma...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Tebib, Jacques, Mariette, Xavier, Bourgeois, Pierre, Flipo, René-Marc, Gaudin, Philippe, Le Loët, Xavier, Gineste, Paul, Guy, Laurent, Mansfield, Colin D, Moussy, Alain, Dubreuil, Patrice, Hermine, Olivier, Sibilia, Jean
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2009
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2714151/
https://ncbi.nlm.nih.gov/pubmed/19549290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/ar2740
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki